Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT05681936
Recruiting Observational

Functional and Structural Changes in the Central Nervous System Following Spinal Cord Injury

NCT05681936 · tracked via the Priya Life Science Switzerland tracker
Phase
Observational
Started
2023-01-01
Last updated
2025-12-15

Condition(s) studied

Spinal Cord InjuriesNeurogenic Bladder DysfunctionDegenerative Cervical Spinal Stenosis

Study summary

Building on recent improvements, state-of-the-art functional MRI will be applied as an advanced diagnostic tool for the lumbosacral cord in spinal cord injury (SCI) patients to characterize the remaining neuronal activity of the motor and sensory neurons. Alterations in the activity pattern will reveal the effect upon task-related spinal cord activity of the lower motor neurons and sensory neurons undergoing trauma-induced neurodegeneration, at a spatial specificity that has not been possible so far. Results of this study will be of crucial importance because SCI patients can only profit from regeneration-inducing therapies if spinal neuronal function is preserved below the level of lesion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age \> 18 years * Informed consent * Willing to take part and follow requirements of the protocol Patients additionally need to fulfil the following study-specific inclusion criteria: Cross-sectional study: * Chronic traumatic SCI (\> 12 months after injury) or * Diagnosed degenerative spondylotic myelopathy (DCM) Longitudinal study: * Acute traumatic SCI (\< 2 months after injury) or * Patients with neurogenic lower urinary tract dysfunction (NLUTD) who undergo routine tibial nerve stimulation (TNS) treatment as part of their rehabilitation (but independently of this study) at Balgrist University Hospital Exclusion Criteria: * Age \< 18 years * Contraindications for MRI (presence of pacemaker or other type of stimulator in the body, presence of metallic foreign body in or on the body, etc.); we will comply with the imaging center's (SCMI) guidelines and in case of doubt we will exclude the participant from the study * No informed consent * History of psychiatric or neurological disease, apart from those induced by SCI (e.g.epilepsy) * History of skull opening or head trauma * Known or suspected non-adherence, drug or alcohol abuse * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. * Women who are pregnant (when uncertain, participants will undergo urine testing) or breastfeeding * Intention to become pregnant during the course of the study * Body mass index (BMI) \> 35 * Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Balgrist University Hospital Zurich Switzerland Recruiting

More University of Zurich trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05681936 on ClinicalTrials.gov ↗ ← All trials in Switzerland